Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

caplacizumab

- PMLiVE

Sanofi’s rare blood disorder drug Cablivi set for European approval

Rare disease drug among notable CHMP recommendations

- PMLiVE

Ablynx reshuffles its board again

Dr Bo Jesper Hansen resigns from the Belgium biotech's board

Robert Freisen joins Ablynx

He will take the role of chief scientific officer, effective March 1

Sanofi reception

Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi

The offer comes at a 110% premium on the Belgian biopharma’s share price

Novo Nordisk target Ablynx reshuffles its board

Dr Bo Jesper Hensen has been elected as biopharma’s new chairman

- PMLiVE

Ablynx knocks-back Novo Nordisk’s second bid

Says the Danish pharma group “fundamentally undervalues” the company

- PMLiVE

Novo Nordisk makes improved €2.6bn offer for Ablynx

Goes back to the Belgian biopharma with a higher bid

- PMLiVE

Belgium’s Ablynx enters the US market

The biopharma firm's new subsidiary will be led by Daniel Schneider

- PMLiVE

Ablynx buoyant as lead antibody aces phase III trial

Caplacizumab met its primary endpoint and reduced aTTP-related death by 74%

Sanofi reception

Sanofi and Ablynx sign €2.4bn nanobody deal

The duo will develop immune-mediated inflammatory disease candidates

- PMLiVE

Ablynx appoints Markus Ewert as chief business officer

He will also join the Belgium-based biopharma firm's executive committee

Ablynx appoints Robert Zeldin chief medical officer

He previously servedat Merck & Co, Novartis and the FDA

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links